Abstract
Brazil, one of the major emerging powers of the world, is marking its presence
in almost every dimension of the world economy, including the generic drugs
industry. Identifying the importance of the country in this significant
domain, the leading market research firm, RNCOS, has come up with research
report "Generic Drugs Market in Brazil (2007-2011)" to provide an updated and
detailed account of the Brazilian generic drugs industry. It examines the
chief reasons why all major generic players are heading to Brazil to
manufacture and sell their drugs.
Brazil is currently the largest market for generic drugs in Latin America and
with the current scenario and positive future projections, it is likely to
emerge amongst the most potential markets for generic drugs in the world.
The generic drugs market in Brazil witnessed an explosive growth of 38.8% and
was valued in excess of US$ 1 Billion in 2006. The market was driven by
several factors such as a supporting political environment, lower cost and
patent expirations of several blockbuster drugs. The market is presently being
dominated by domestic generic manufacturers; however, the presence of foreign
firms in the market is increasing rapidly.
The growth of the market is expected to remain strong with generics expected
to occupy 22.8% of the total market by 2011, enabling Brazil to become one of
the largest generic markets in the world. However, despite the strong growth,
several challenges still remain to be tackled, including the prevalence of
cheaper non-bioequivalent "similar drugs", low prescriptions from the private
sector, and low penetration levels in the private sector.
Key Findings
- Generics in Brazil occupy nearly 9.5% of the overall pharmaceutical market
in terms of sales value.
- The domestic generic firms of Brazil are over-dependent on the domestic
market and have less participation in foreign markets.
- The Brazilian government has made it a norm to prescribe generics in the
public sector.
- Strengthening of the Brazilian Real has increased the margins of domestic
players who import raw materials to manufacture generic drugs. Currently, the
domestic industry mainly focuses on finishing generic pharmaceuticals.
- One of the biggest opportunities in the generic sector lies in the
Antiretroviral segment.
- Non-bioequivalent "similar drugs", which are considerably cheaper than
generics, are prevalent in the pharmaceutical market.
- Cardiovascular diseases are the biggest death cause in Brazil.
- Medley and EMS Sigma are the biggest generic manufacturers in Brazil.
Key Issues & Facts Analyzed
- Evaluation of past, current and future market trends.
- Discussion about the size and growth of the market.
- Analysis of healthcare indicators.
- Future prospects of the generics market.
- Analysis of various challenges and opportunities before the industry.
- Profile discussion of key players in this sector.
Key Players Analyzed
This section provides the overview, key facts, and financial information of
prominent players in the Brazil Generics Market, such as Medley, EMS Sigma
Pharma, Eurofarma Laboratorios Ltd, Aché Pharmaceutical Laboratories
S/A and Ranbaxy.
Research Methodology Used
Information Sources
The information has been sourced from books, newspapers, trade journals, and
white papers, industry portals, government agencies, trade associations,
monitoring industry news and developments, and over 3000 paid databases.
Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear
regression analysis using software tools, judgmental forecasting, and cause
and effect analysis.
View Cart
